trending Market Intelligence /marketintelligence/en/news-insights/trending/HH5m-2kSaHe3IZNlF0XQng2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

CSL books 11% YOY increase in FY'19 profit

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

CSL books 11% YOY increase in FY'19 profit

CSL Ltd.'s earnings climbed 11% on a reported basis and 17% on a constant currency basis for the fiscal year ended June 30.

Net profit after tax for the fiscal year 2019 was about US$1.92 billion on a reported basis, or US$4.24 per share, up from US$1.73 billion, or US$3.82 per share, in the year-ago period.

The Australia-based biotechnology company's total revenue rose to US$8.54 billion on a reported basis from US$7.92 billion a year earlier.

Revenue was driven by continued growth of the company's immunoglobulin products and higher sales of its specialty products Haegarda and Kcentra, as well as the evolution of CSL's hemophilia therapies portfolio. The company noted that its Seqirus influenza vaccines business also delivered on the strategy, with strong profit growth.

CSL's dividend for the year saw an 8% increase to US$1.85 per share from US$1.72 in the year-ago period.

For the fiscal year 2020, CSL expects its net profit after tax to be in the range of US$2.05 billion to US$2.11 billion, taking into the account the one-off financial headwind of transitioning to a new model of direct distribution in China.